Needham Reiterates Buy on Sage Therapeutics, Maintains $70 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $70 price target.
August 07, 2023 | 8:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Sage Therapeutics and maintained a $70 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $70 price target indicates a positive outlook for Sage Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100